Supplementary Materials

Cumulative BZD doses	Univariate model		Multivariate model†	
	Crude HR (95% CI)	p value	Adjusted HR (95% CI)	p value
Non-user	1 (ref.)		1 (ref.)	
All BZD user	1.75 (1.60–1.91)	< 0.001	1.94 (1.77–2.14)	< 0.001
1–90 cDDDs	1.83 (1.66–2.02)	< 0.001	1.96 (1.77–2.18)	< 0.001
91–365 cDDDs	1.72 (1.50–1.98)	< 0.001	1.89 (1.64–2.18)	< 0.001
>365 cDDDs	1.45 (1.24–1.70)	< 0.001	1.92 (1.63–2.25)	< 0.001

Table S1. Sensitivity analysis of risk of contracting pneumonia after stroke according to BZD-use status

For the sensitivity analysis, pneumonia events were defined as those diagnosed during the follow-up

period regardless of whether the diagnosis was rendered in an inpatient or outpatient service.

*Per 1000 person-years.

[†]Multivariate Cox proportional hazard regression model, adjusting for all baseline characteristics (listed in Table 1) and competing mortality.

Abbreviations: BZD, benzodiazepine; HR, hazard ratio; CI, confidence interval; cDDDs, cumulative defined daily doses